Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Wednesday, 10 February 2021 09:15

Hatim Husain

Written by
Dr. Husain has developed a translational research focus to bring discoveries from bench-to-bedside. His efforts include expanding tools for tracking cancer growth specifically through circulating tumor DNA analyses and investigating how the genome can provide clues to optimal treatments and new therapies. Specifically, Dr. Husain's work has involved understanding mechanisms of resistance to targeted therapies, including anti-epidermal growth factor receptor (EGFR) treatments, and further characterizing the mechanisms of immunogenic cell death in cancer cells.
Wednesday, 10 February 2021 09:15

Leora Horn

Written by
In my role, I lead the company
Wednesday, 10 February 2021 09:15

Kristin Higgins

Written by
Kristin Higgins, M.D., specializes in the treatment of lung cancer. She completed residency in Radiation Oncology at Duke University, as well as an internship in internal medicine. She attended medical school at Tulane University in New Orleans, LA. She earned a B.S. in neuroscience at Vanderbilt University and graduated magna cum laude. Throughout her training Dr. Higgins received numerous honors, including induction into Alpha Omega Alpha Honor Medical Society, and the Roentgen Resident/Fellow Research Award at Duke University, and the ASCO Bradley Stuart Beller Merit Award. Dr. Higgins is an Associate Professor within the Emory School of Medicine and serves as the Medical Director of Radiation Oncology at the main campus location. She leads numerous Winship Clinical Trials that examine innovative treatment approaches in the treatment of lung cancer. One such clinical trial is LU005, A NRG Oncology/Alliance study comparing chemoradiation with or without immunotherapy for limited stage small cell lung cancer. This clinical trial is funded by the National Cancer Institute and provides a novel treatment approach for patients with newly diagnosed small cell lung cancer. Dr. Higgins has authored and coauthored over 60 scientific, peer-reviewed manuscripts and abstracts and given many oral presentations at national and international meetings. Dr. Higgins is a member of multiple professional organizations including the American Society for Radiation Oncology, the American Board of Radiology, the International Association for the study of Lung Cancer, The American Society of Clinical Oncology, and the Radiation Therapy Oncology Group.
Wednesday, 10 February 2021 09:15

John Heymach

Written by
John V. Heymach, MD, PhD is Chair of the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. As a physician-scientist, his research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for selecting patients most likely to benefit from targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer, adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard of care regimens or undergoing clinical testing. He holds the David Bruton, Jr. Chair in Cancer Research. He attended Harvard College, where he graduated magna cum laude with a Chemistry B.A. degree and received his MD and PhD from Stanford. Dr. Heymach is a member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP) and is a Fellow of the American Association for the Advancement of Science (AAS). He has been awarded the Finneran Family Prize for translational cancer research and the Potu N. Rao Award for Excellence in Basic Science.
Wednesday, 10 February 2021 09:15

Roy Herbst

Written by
Roy S. Herbst, MD, PhD is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine. He is a fellow of the American Society of Clinical Oncology and the American College of Physicians, an elected member of the Association of American Physicians, and an elected member of the boards of directors for both AACR and the IASLC.

Dr. Herbst is a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments to patients, serving as principal investigator for trials leading to approval of several therapies revolutionizing the field and greatly enhancing patients’ lives.

He has more than 300 publications to his name, and his work published in Nature was awarded Clinical Research Forum’s 2015 Herbert Pardes Clinical Research Excellence Award. The NCI Lung SPORE Dr. Herbst leads has identified new mechanisms of sensitivity and resistance to immunotherapy. His work on "umbrella” trials, such as Lung MAP, has galvanized the field by developing public-private partnerships to conduct large clinical studies. He is a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes).
Wednesday, 10 February 2021 09:15

Brian Henick

Written by
Dr. Henick is an Assistant Professor of Medicine at Columbia University with clinical and research interests in novel biomarker and drug development for patients with thoracic malignancies.
Wednesday, 10 February 2021 09:15

Matthew Hellmann

Written by
I am a medical oncologist who specializes in the care of patients with lung cancers, particularly non small-cell lung cancers. I am dedicated to identifying better treatments for people with all stages of disease and to providing compassionate care for patients and their families. My research focuses on developing innovative and effective ways to harness the body’s immune system to fight cancer.
Wednesday, 10 February 2021 09:15

Rebecca Heist

Written by
Dr. Rebecca Heist is an Associate Professor of Medicine at Harvard Medical School and thoracic oncologist at Massachusetts General Hospital.
Wednesday, 10 February 2021 09:15

Aparna Hegde

Written by
Thoracic Oncologist and clinical trialist at O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham. Focused on all aspects of mechanisms and management of immune related adverse events.
Wednesday, 10 February 2021 09:15

Kai He

Written by
I am a medical oncologist at The Ohio State University Thoracic Oncology Center, who specializes in treating lung cancer patient and developing cutting-edge treatments for these patients. As a faculty member of the OSUCCC Translational Therapeutics Program, Pelotonia Institute for Immuno-Oncology and the OSU Biomedical Sciences Graduate Program, my research focuses on cancer epigenetics, genomics and immunology, and their associated novel biomarker and therapeutic development in lung cancer. My lab studies the determinants for the response and resistance to immunotherapy in lung cancer, and the dynamic immune landscape evolution related to immunotherapy. I serve as an investigator on multiple clinical trials, including novel combined immunotherapy, adaptive T cell therapy and target therapy in lung cancer. I also conduct the translational studies of immunotherapy trials in lung cancer, correlating molecular and immune phenotyping biomarkers with outcomes.
Page 366 of 371